The FDA decision on Liquidia Technologies Inc.’s (LQDA) product candidate LIQ861 is expected on November 24, 2020.LIQ861, a dry powder inhalation of treprostinil, is proposed for the treatment of pulmonary arterial hypertension (PAH).Liquidia is seeking approval for LIQ861 under the 505(b)(2) regulatory pathway and United Therapeutics Corp.’s (UTHR) Tyvaso, a nebulized treprostinil solution, is the Reference Listed Drug for the LIQ861 NDA.Liquidia and United Therapeutics are locked in a patent dispute over Tyvaso. In a patent suit filed in June this year, United Therapeutics had alleged that Liquidia Infringed on two patents for Tyvaso, which are set to expire in December 2028.LQDA closed Friday’s (Oct.23, 2020) trading at $4.54, up 0.78%.